Floatz logo

som230

Lobular Carcinoma in Situ (LCIS)

NYU Langone HealthPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Lobular Carcinoma in Situ (LCIS) cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB
Oxybutynin
Academic and Community Cancer Research United
Phase 3BB
Letrozole
Alliance for Clinical Trials in Oncology
Phase 3BB
Metformin
Alliance for Clinical Trials in Oncology
Phase 3B
EXEMESTANE
Alliance for Clinical Trials in Oncology
Phase 3B

View all 20 →

Same molecule, other indications

som230 is also rated in:

breast intraductal proliferative lesionDormant
CC
Indicative ·
47 / 100
View asset →
atypical lobular breast hyperplasiaDormant
CC
Indicative ·
47 / 100
View asset →
ductal breast carcinoma in situDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →